Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | RBP4 | P02753 | 2/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661780 | 1.00 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL4618974 | 0.92 | CYP2C9 (0.66) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL3655992 | 0.82 | HCRTR1 (0.51) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL3655989 | 0.82 | HCRTR1 (0.51) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL5390608 | 0.81 | MEN1 (0.58) | CYP2C9CYP2C19MAPK14MGLLHSD11B1 | |
| SCHEMBL4245060 | 0.80 | HSD11B1 (0.61) | CYP2C9CYP2C19MAPK14MGLLHSD11B1 | |
| SCHEMBL3661733 | 0.80 | HSD11B1 (0.61) | CYP2C9CYP2C19MAPK14MGLLHSD11B1 | |
| SCHEMBL4635407 | 0.80 | CYP2C9 (0.52) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL17856075 | 0.80 | HSD11B1 (0.54) | MGLLHSD11B1 | |
| SCHEMBL29783896 | 0.79 | CYP2C9 (0.68) | CYP2C9CYP2C19HTR2BMAPK14MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903372-B | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | CYP2C9 510/4885CYP2C19 407/4885HTR2B 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.